Thumbay Labs, a mainstay of the UAE’s lab industry that accounts for approximately one-fifth of the entire national market share, recently said it plans to open
advanced testing facilities, widen its portfolio and further increase its production this year.
Along with conventional expansion methods such as teaming up
with hospitals and stand-alone locations, the company’s strategy will focus on
targeting specialized areas such as diabetology, genetics, women’s health and
children’s health. Its NeoScreen patented product, for example, is a newborn
screening device marketed at a competitive price in the emirates.
Thumbay Labs Director P. K. Menon said the
company is seeking partners as it introduces newer technologies.
Thumbay Labs is the only
laboratory enterprise in the Northern Emirates with accreditation from the Washington,
D.C.-based College of American Pathologists (CAP) and operates under the
auspices of the Center for Advanced Biomedical Research and Innovation (CABRI) at
the Gulf Medical University in Ajman.
“CABRI plays an important role in enhancing the quality
of training for students undergoing master’s degrees at Gulf Medical University,” Thumbay Moideen, who founded Thumbay Group in 1997 and serves as president, said.
“It also plays important part in enhancing student/faculty research and
coordinates contracted research through Thumbay Group’s hospitals.”
The company, which also operates lab facilities in Hyderabad,
India, expects to open more clinical outlets in the near
future to accommodate imaging, cardiology and neurology testing, occupational
health assessments, allergy evaluations and preventive health initiatives.
